TABLE 1.
Demographic characteristics and anti-HBs levels in hepatitis B vaccine booster study participants at year 7 to 9 follow-upa
| Characteristic | Value for vaccine group |
Total value (n = 104) | P value comparing groups | ||
|---|---|---|---|---|---|
| AS (n = 17) | AR (n = 38) | CR (n = 49) | |||
| Demographic | |||||
| No. (%) of males | 7 (41) | 14 (37) | 28 (57) | 55 (53) | 0.148 |
| Mean (SD) age at booster, yrs | 13.8 (0.59) | 11.7 (1.25) | 5.9 (0.73) | 9.3 (3.44) | <0.001 |
| Mean (SD) age at follow-up, yrs | 22.6 (0.55) | 19.9 (1.09) | 14.3 (0.84) | 17.7 (3.48) | <0.001 |
| Mean (SD) elapsed time since booster, yrs | 8.7 (0.33) | 8.3 (0.58) | 8.38 (0.48) | 8.39 (0.52) | 0.005 |
| Anti-HBs levels (mIU/ml) | |||||
| Prebooster GMC (95% CI) | 2.13 (0.7, 6.5) | 1.53 (0.92, 2.54) | 3.28 (1.94, 5.54) | 2.31 (1.61, 3.32) | 0.156 |
| Minimum–maximum | 0–213 | 0–133 | 0–309 | 0–309 | |
| Week 2 postbooster GMC (95% CI) | 59 (67.4, 994) | 618 (344, 1,112) | 1,274 (736, 2,206) | 754 (498, 1,141) | 0.018 |
| Minimum–maximum | 0–36,947 | 20.2–28,561 | 10.6–64,676 | 0–64,676 | |
| Week 4 postbooster GMC (95% CI) | 246 (71.4, 847) | 472 (273, 817) | 804 (485, 1,335) | 544 (373, 794) | 0.074 |
| Minimum–maximum | 18.4–34,533 | 34.1–28,561 | 10.6–22,463 | 10.6–34,533 | |
| Years 7–9 postbooster GMC (95% CI) | 11.0 (3.7, 32.4) | 5.6 (3.0, 10.5) | 5.6 (3.4, 9.3) | 6.3 (4.3, 9.1) | 0.417 |
| Minimum–maximum | 0–1,029 | 0–215 | 0–238 | 0–1,029 | |
a
CI, confidence interval. Bolded values represent statistical significance.